摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N,N'-bis(2'-tritylaminoethyl)-1,6-diaminohexane | 336876-30-3

中文名称
——
中文别名
——
英文名称
N,N'-bis(2'-tritylaminoethyl)-1,6-diaminohexane
英文别名
N,N'-bis[2-(tritylamino)ethyl]hexane-1,6-diamine
N,N'-bis(2'-tritylaminoethyl)-1,6-diaminohexane化学式
CAS
336876-30-3
化学式
C48H54N4
mdl
——
分子量
686.984
InChiKey
ATIZXQXXUBAQOD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    9.3
  • 重原子数:
    52
  • 可旋转键数:
    21
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    48.1
  • 氢给体数:
    4
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    Half-sandwich ruthenium (II) compounds comprising nitrogen containing ligands for treatment of cancer
    摘要:
    可能用于癌症治疗和/或预防的化合物的化学式为(I),其中:R1、R2、R3、R4、R5和R6独立地表示H、烷基、-CO2R′、芳基或烷基芳基,后两个基团在芳香环上可以选择性地取代;R′表示烷基、芳基或烷基芳基;X为卤素、H2O、(R′)(R″)SO、R′CO2-或(R′)(R″)C═O,其中R″表示烷基、芳基或烷基芳基;Y为计数离子;m为0或1;q为1、2或3;C′为C1到C12的烷基,可选择性地取代或位于烷基链上,与两个A基团相连;p为0或1,当p为0时,r为1,当p为1时,r为2,而A和B分别为:每个独立的N-供体腈配体;或B为卤素,A为一个N-供体吡啶配体,在吡啶环的一个或多个碳原子上可以选择性地取代;或p为0,A为NR7R8,B为NR9R10,其中R7、R8、R9和R10独立地表示H或烷基,而A和B由一个烷基链相连,可选择性地取代或位于烷基链上,或p为1,A为NR7,B为NR9R10,其中R7、R9和R10如上定义,而A和B由一个烷基链相连,可选择性地取代。
    公开号:
    US20050239765A1
点击查看最新优质反应信息

文献信息

  • [EN] HALF-SANDWICH RUTHENIUM (II) COMPOUNDS COMPRISING NITROGEN CONTAINING LIGANDS FOR TREATMENT OF CANCER<br/>[FR] COMPOSES DE RUTHENIUM (II) DEMI-SANDWICH COMPRENANT DE L'AZOTE CONTENANT DES LIGANDS UTILISES DANS LE TRAITEMENT DU CANCER
    申请人:UNIV COURT THE UNIVERSITY OF E
    公开号:WO2001030790A1
    公开(公告)日:2001-05-03
    Compounds which may be used in the treatment and/or prevention of cancer have the formula (I) wherein: R?1, R2, R3, R4, R5 and R6¿ independently represents H, alkyl, -CO¿2?R', aryl or akylaryl, which latter two groups are optionally substituted on the aromatic ring; R' represent alkyl, aryl or alkaryl; X is halo, H2O, (R')(R'')SO, R'CO2?-¿ or (R')(R'')C=O, where R'' represents alkyl, aryl or alkaryl; Y is a counterion; m is 0 or 1; q is 1, 2 or 3; C' is C¿1? to C12 alkylene, optionally substituted in or on the alkylene chain, bound to two A groups; p is 0 or 1 and r is 1 when p is 0 and r is 2 when p is 1; and A and B are: each independently N-donor nitrile ligands; or B is halo and A is an N-donor pyridine ligand, optionally substituted at one or more of the carbon atoms of the pyridine ring; or p is 0, A is NR?7R8¿ and B is NR9R10, wherein R?7, R8, R9 and R10¿ independently represent H or alkyl, and A and B are linked by an alkylene chain, optionally substituted in or on the alkylene chain; or p is 1, A is NR7 and B is NR9R10, wherein R?7, R9 and R10¿ are as previously defined, and A and B are linked by an alkylene chain, optionally substituted.
    可以用于癌症治疗和/或预防的化合物的化学式为(I),其中:R?1,R2,R3,R4,R5和R6¿分别代表H,烷基,-CO¿2?R',芳基或akylaryl,后两个基团在芳环上可选地取代;R'代表烷基,芳基或alkaryl;X为卤素,H2O,(R')(R'')SO,R'CO2?-¿或(R')(R'')C=O,其中R''代表烷基,芳基或alkaryl;Y为一个计数离子;m为0或1;q为1、2或3;C'为C¿1?到C12烷基,可选地取代或结合到两个A基团上的烷基链;p为0或1,当p为0时,r为1,当p为1时,r为2;A和B是:每个独立的N-供体腈配体;或B为卤素,A为一个N-供体吡啶配体,可选地取代吡啶环的一个或多个碳原子;或p为0,A为NR?7R8¿,B为NR9R10,其中R?7,R8,R9和R10¿独立地代表H或烷基,并且A和B由一个烷基链连接,可选地取代或结合到烷基链上;或p为1,A为NR7,B为NR9R10,其中R?7,R9和R10¿如前所述,A和B由一个烷基链连接,可选地取代或结合到烷基链上。
  • Half-sandwich ruthenium (II) compounds comprising nitrogen containing ligands ligands for treatment of cancer
    申请人:University Court
    公开号:US20040220166A1
    公开(公告)日:2004-11-04
    Compounds which may be used in the treatment and/or prevention of cancer have the formula (I) wherein: R 1 , R 2 , R 3 , R 4 , R 5 and R 6 independently represents H, alkyl, —CO 2 R′, aryl or alkylaryl, which latter two groups are optionally substituted on the aromatic ring; R′ represent alkyl, aryl or alkaryl; X is halo, H 2 O, (R′)(R″)SO, R′CO 2 — or (R′)(R″)C═O, where R″ represents alkyl, aryl or alkaryl; Y is a counterion; m is 0 or 1; q is 1, 2 or 3; C′ is C 1 to C 12 alkylene, optionally substituted in or on the alkylene chain, bound to two A groups; p is 0 or 1 and r is 1 when p is 0 and r is 2 when p is 1; and A and B are: each independently N-donor nitrile ligands; or B is halo and A is an N-donor pyridine ligand, optionally substituted at one or more of the carbon atoms of the pyridine ring; or p is 0, A is NR 7 R 8 and B is NR 9 R 10 , wherein R 7 , R 8 , R 9 and R 10 independently represent H or alkyl, and A and B are linked by an alkylene chain, optionally substituted in or on the alkylene chain, or p is 1, A is NR 7 and B is NR 9 R 10 , wherein R 7 , R 9 and R 10 are as previously defined, and A and B are linked by an alkylene chain, optionally substituted.
    可能用于癌症治疗和/或预防的化合物具有以下公式(I):其中:R1、R2、R3、R4、R5和R6独立地表示H、烷基、— R′、芳基或烷基芳基,后两个基团在芳香环上可以选择性地被取代;R′代表烷基、芳基或烷基芳基;X是卤、H2O、(R′)(R″)SO、R′CO2—或(R′)(R″)C═O,其中R″代表烷基、芳基或烷基芳基;Y是一个计数离子;m为0或1;q为1、2或3;C′是C1到C12的烷基,可以选择性地在烷基链上或内取代,与两个A基团结合;p为0或1,当p为0时r为1,当p为1时r为2;A和B分别为:每个独立的N-供体腈配体;或B为卤,A为一个N-供体吡啶配体,可以在吡啶环的一个或多个碳原子上选择性地取代;或p为0,A为NR7R8,B为NR9R10,其中R7、R8、R9和R10独立地表示H或烷基,并且A和B由一个烷基链连接,可以选择性地在烷基链上或内取代,或p为1,A为NR7,B为NR9R10,其中R7、R9和R10如前所述,且A和B由一个烷基链连接,可以选择性地在烷基链上或内取代。
  • Ruthenium (II) compounds for use in the therapy of cancer
    申请人:Morris Robert Edward
    公开号:US06936634B2
    公开(公告)日:2005-08-30
    Compounds which may be used in the treatment and/or prevention of cancer have the formula (I): wherein R 1 and R 2 together with the ring to which they are bound represent a saturated or unsaturated carbocyclic or heterocyclic group
    可能用于癌症治疗和/或预防的化合物具有以下公式(I): 其中,R1和R2与它们所结合的环一起表示饱和或不饱和的碳环或杂环基团。
  • HALF-SANDWICH RUTHENIUM (II) COMPOUNDS COMPRISING NITROGEN CONTAINING LIGANDS FOR TREATMENT OF CANCER
    申请人:THE UNIVERSITY COURT OFTHE UNIVERSITY OF EDINBURGHOF OLD COLLEGE
    公开号:EP1224192A1
    公开(公告)日:2002-07-24
  • RUTHENIUM (II) COMPOUNDS FOR USE IN THE THERAPY OF CANCER
    申请人:THE UNIVERSITY COURT, THE UNIVERSITY OF EDINBURGH
    公开号:EP1294732B1
    公开(公告)日:2004-08-18
查看更多

同类化合物

(3-三苯基甲氨基甲基)吡啶 非马沙坦杂质1 隐色甲紫-d6 隐色孔雀绿-d6 隐色孔雀绿 隐色乙基结晶紫 降钙素杂质10 重氮四苯基乙烷 酸性黄117 酸性蓝119 酚酞啉 酚酞二硫酸钾水合物 萘,1-甲氧基-3-甲基 苯酚,4-(1,1-二苯基丙基)- 苯甲醇,4-溴-a-(4-溴苯基)-a-苯基- 苯甲醇,2-氨基-5-氯-a-乙烯基-a-苯基- 苯甲酸,4-(羟基二苯甲基)-,甲基酯 苯甲酸,3-[[2-[[(1,1-二甲基乙氧基)羰基]氨基]-3-[(三苯代甲基)硫代]丙基]氨基]-,(R)- 苯甲基N-[(2(三苯代甲基四唑-5-基-1,1联苯基-4-基]-甲基-2-氨基-3-甲基丁酸酯 苯基双-(对二乙氨基苯)甲烷 苯基二甲苯基甲烷 苯基二[2-甲基-4-(二乙基氨基)苯基]甲烷 苯基{二[4-(三氟甲基)苯基]}甲醇 苯基-二(2-羟基-5-氯苯基)甲烷 苄基2,3,4-三-O-苄基-6-O-三苯甲基-BETA-D-吡喃葡萄糖苷 苄基 5-氨基-5-脱氧-2,3-O-异亚丙基-6-O-三苯甲基呋喃己糖苷 苄基 2-乙酰氨基-2-脱氧-6-O-三苯基-甲基-alpha-D-吡喃葡萄糖苷 苄基 2,3-O-异亚丙基-6-三苯甲基-alpha-D-甘露呋喃糖 苄基 2,3,4-三-O-(苯基甲基)-6-O-(三苯基甲基)-ALPHA-D-吡喃甘露糖苷 芴甲氧羰基-4-叔丁酯-天冬酰胺-S-三氯苯甲基-L-半胱氨酸 膦酸,1,2-乙二基二(磷羧基甲基)亚氨基-3,1-丙二基次氮基<三价氮基>二(亚甲基)四-,盐钠 脱氢奥美沙坦-2三苯甲基奥美沙坦脂 美托咪定杂质28 绿茶提取物茶多酚陕西龙孚 结晶紫 磺基琥珀酰亚胺基-4-[2-(4,4-二甲氧基三苯甲基)]丁酸酯 磷,三(4-甲氧苯基)甲基-,碘化 碱性蓝 硫代硫酸氢 S-[2-[(3,3,3-三苯基丙基)氨基]乙基]酯 盐酸三苯甲基肼 白孔雀石绿-d5 甲酮,(反-4-氨基-4-甲基环己基)-4-吗啉基- 甲基三苯基甲基醚 甲基6-O-(三苯基甲基)-ALPHA-D-吡喃甘露糖苷三苯甲酸酯 甲基3,4-O-异亚丙基-6-O-三苯甲基-beta-D-吡喃半乳糖苷 甲基3,4-O-异亚丙基-2-O-甲基-6-O-三苯甲基吡喃己糖苷 甲基2-甲基-N-{[4-(三氟甲基)苯基]氨基甲酰}丙氨酸酸酯 甲基2,3,4-三-O-苯甲酰基-6-O-三苯甲基-ALPHA-D-吡喃葡萄糖苷 甲基2,3,4-三-O-苄基-6-O-三苯甲基-ALPHA-D-吡喃葡萄糖苷 甲基2,3,4-三-O-(苯基甲基)-6-O-(三苯基甲基)-ALPHA-D-吡喃半乳糖苷